Eli Lilly and Company · Moat analysis

Report previewLLY.USReport date Last updated
← Back to reports
Report contents
01

Industry landscape

Where the company competes: a US duopoly where payers set the price

Eli Lilly sells branded prescription medicines, but its center of gravity now sits in one therapeutic class: incretin-based drugs for type 2 diabetes and obesity. Two brands carry the company. Mounjaro, the diabetes product, brought in $8.66 billion worldwide in the first quarter of 2026, up 125% year over year; Zepbound, the obesity product, generated $4.16 billion in US sales, up 80%. Total first-quarter revenue rose 56% to $19.80 billion, and the company lifted full-year 2026 guidance to $82 billion to $85 billion from $80 billion to $83 billion, as it reported on April 30, 2026. No other part of the portfolio operates near that scale, so the competitive question that matters is narrow: who controls the market for GLP-1 and GIP-based therapies, and on what terms.

The value chain runs from peptide chemistry to payer contracts. Lilly synthesizes active ingredients and assembles injector pens in-house at a scale few rivals match, an advantage built on years of capital spending on sterile fill-finish capacity. Downstream, patients are mostly reached through intermediaries. In the US, three wholesalers and a handful of pharmacy benefit managers stand between Lilly and the prescription; overseas, national health systems and distributors do the same job with more bargaining leverage. Buyers are concentrated on both sides of the Atlantic, which may be one reason realized prices fall even when demand surges. A growing slice of volume bypasses intermediaries, because patients in Europe, China and Brazil frequently pay cash, and chief executive Dave Ricks pointed to the "depth and breadth of the consumer market" outside the US.

The arena is global in cost and local in price. Manufacturing and clinical trials scale worldwide; reimbursement, formulary placement and the price a health system will pay are set country by country. First-quarter US revenue rose 43% to $12.1 billion on a 49% volume increase, partly offset by lower realized prices. Revenue outside the US rose 81% to $7.7 billion on 95% volume growth, again trimmed by price. Lilly was slow to launch internationally during the 2024 supply crunch and is now three or four quarters into major European, Chinese and Brazilian markets. Those launches explain the ex-US growth rate; they say nothing yet about durable share outside the US.

Concentration in the US is extreme. Lilly's own earnings presentation put its share of the US obesity and diabetes drug market at 60.1% in the first quarter of 2026 and Novo Nordisk's at 39.4%.

PlayerShare of the US obesity and diabetes drug market, Q1 2026
Eli Lilly60.1%
Novo Nordisk39.4%
All other suppliersroughly 0.5% (arithmetic residual)

Two caveats matter. The denominator is the company's own definition, and it is not broken out in a way that shows which products beyond the two leaders are counted. And the split covers the US only: no comparable share estimate for Europe or China is publicly available, even though Lilly's revenue is growing faster there from a smaller base. A third supply route was effectively squeezed out of the legal market when the FDA ended the shortage designations that had let compounding pharmacies copy the drugs.

Barriers to entry: high. When the leaders fit on one hand, entry barriers are usually high, and that test is met here without strain. A credible entrant needs peptide manufacturing at commercial scale, outcome trials running to tens of thousands of patients, a patent estate, and formulary access the two incumbents already hold. What the barrier protects against is a new entrant; it does less against the existing rival. Lilly and Novo Nordisk are racing on oral formulations and next-generation combinations, and the market is still expanding through new patients rather than swapping existing ones. More than 20,000 people started Lilly's new obesity pill, Foundayo, in its first few weeks, at more than 1,000 a day, and Ricks said 80% of them had not used a GLP-1 before.

Price is the weak seam. Lilly's 2026 outlook assumes continued pricing pressure from the drug-pricing agreement with the Trump administration and lower cash-pay Zepbound prices, with Medicare coverage of obesity drugs arriving later in the year. Medicare can add volume; it does not restore price. If volume growth slows while realized prices keep sliding, the duopoly's economics deteriorate even with no new competitor. A rival oral drug with better tolerability, or a third player winning broad formulary access, would test the moat more directly than any pipeline announcement. So far the evidence shows scale that is hard to replicate and pricing power that is already eroding.

02

Competitive advantage

Does the company have a moat? Yes, and both tests hold

Overall rating: Strong. Eli Lilly holds the larger half of a two-supplier market and earns a return on equity several times its cost of capital, and it has held both through a period in which revenue more than doubled. Those are the two tests that matter. Concentration shows entrants are not getting in; persistent excess profit shows the gains are not a one-off feat of management that a competitor can copy. Lilly clears both. The soft spot is price: third-quarter 2026 revenue rose 39% to $24.4 billion on a 53% volume increase that a 15% decline in realized prices partly offset, the company reported on October 29, 2026.

Market position: Strong

Lilly's own first-quarter 2026 earnings presentation put its share of the US obesity and diabetes drug market at 60.1% and Novo Nordisk's at 39.4%, leaving roughly half a percentage point for every other supplier combined. Lilly ranks first in the market that now generates most of its revenue.

Discount the denominator. Lilly chose it, and the presentation does not itemize which products beyond the two leaders it counts. The ranking survives that discount, because no third manufacturer has built meaningful scale in these drug classes in the US, and the compounded copies that briefly filled the gap are gone after the FDA ended the shortage designations that had allowed them.

Stability of the position: Fairly Strong

No five-year series of Lilly's market share is public, so the trend has to be read from adjacent evidence, and that evidence points one way. Revenue climbed from $28.3 billion in fiscal 2021 to $65.2 billion in fiscal 2025, with management guiding to $91 billion to $92 billion for 2026. Over the same stretch, gross margin rose from 74.2% to 83.8%, and it reached 83.9% in the third quarter of 2026. A position that was being eaten away would not normally come with expanding margins, and certainly not while a rival holds close to 40% of the same market.

Profitability: Strong
Fiscal yearRevenue (USD bn)Net income (USD bn)Gross marginNet marginROE
202128.35.674.2%19.7%76.4%
202228.56.376.8%21.9%63.6%
202334.15.279.2%15.4%48.9%
202445.010.681.3%23.5%84.8%
202565.220.683.8%31.7%77.8%

Figures come from Lilly's annual filings; the fiscal 2025 ROE is calculated on year-end equity of $26.5 billion. ROE is the substitute here for ROIC, because the company's balance sheet does not separate operating invested capital cleanly from a large and growing stack of non-debt liabilities. The five-year average lands near 70%, and the weakest year, 2023, is still triple the 15% to 25% band that signals a durable advantage. Two caveats. The equity base is thin at $26.5 billion against $85.9 billion of total liabilities, so leverage lifts the ratio. And the 2023 dip came from research and acquired in-process charges, which is the cost of running a portfolio this size, not a sign of pricing weakness.

Margins and scale: Strong

Gross margin gained 9.6 percentage points between fiscal 2021 and fiscal 2025, and net margin went from 19.7% to 31.7%. Lilly's share premium over its only real rival, roughly 20 points in the US incretin market, matters because manufacturing, clinical development and sales coverage are largely fixed costs. That base pays for simultaneous launches across oncology, immunology and neuroscience, and for head-to-head trials such as retatrutide against Ozempic 2 mg in type 2 diabetes, where the company reported positive topline results in the third quarter of 2026. Operating cash flow reached $16.8 billion in fiscal 2025, up from $4.2 billion in 2023. The bill shows up in investing outflows of $9.3 billion in 2024 and $11.0 billion in 2025, which is what defending a share position costs in this business.

Overall assessment: a durable moat, priced off falling prices

The concentration test is met without strain, and the profitability test is met by a wide margin, so the overall rating is Strong. What keeps it from being cleaner is that Lilly grows by winning new patients in an expanding market while its realized prices slide, and the two forces do not have to stay in the same ratio forever.

Where the advantage comes from: capacity plus a chronic-use franchise

Three sources carry the advantage, in descending order of weight: manufacturing and development scale, demand-side captivity rooted in chronic therapy, and regulatory exclusivity over the molecules. The first two combine into the strongest pattern the framework recognizes, scale paired with customer lock-in, but the lock-in leg is the weaker of the two here. That is why durability depends more on capacity and price than on patients being unable to leave.

Supply advantage: peptide capacity rivals cannot rent quickly — Fairly Strong

Tirzepatide is a peptide, made through synthesis and fermentation and filled into sterile injector pens. The binding constraint in this industry is the sterile fill-finish step, not the molecule. Lilly owns that step. Net property, plant and equipment went from $10.1 billion at the end of 2022 to $17.1 billion at the end of 2024, and the company announced further manufacturing expansions in Texas and Virginia alongside its third-quarter 2026 results.

The chain from capacity to economics runs through launch timing. When Lilly was supply-constrained in 2024, it could not open European, Chinese and Brazilian markets on schedule. Capacity determines when revenue can start, and revenue in these drug classes compounds because patients stay on treatment. Volume outside the US grew 76% in the third quarter of 2026 while US volume grew 41%, which is what a company looks like when the constraint has eased. Gross margin rose a percentage point in the same quarter, so the new plants are running at acceptable cost.

What limits the rating is that this is an asset advantage, not a secret. Novo Nordisk builds comparable plants, contract manufacturers can be hired, and the chemistry is published. Sterile peptide capacity takes years to build and qualify, and that is exactly the size of the lead Lilly holds: years of launch windows, not decades. Development scale works the same way. A company that runs a head-to-head Phase 3 trial against a rival's best-selling drug, a Phase 3 in hand and foot atopic dermatitis with Ebglyss, and moves EloraTZP into Phase 3 in the fourth quarter of 2026 spreads fixed trial costs across more shots on goal than most competitors can fund. It is a genuine edge and a copyable one.

Demand advantage: chronic use and formulary slots — Moderate

Patients take these drugs continuously. Stopping brings weight back and muscle loss of glycemic control, so refills have an automatic quality. Prescribers rarely move a patient who is tolerating a drug well, and once a payer covers a brand, switching a patient means a new prior authorization. Those are real frictions.

They are weaker than they look. The two leading products are close substitutes: weekly injectables that produce large weight loss over a similar treatment period. A formulary change or an aggressive discount can move a patient at the next refill, and Lilly's own numbers show how much of the growth comes from price. US volume rose 41% in the third quarter of 2026 while realized US prices fell 7%. Outside the US, volume rose 76% against a 29% price decline, largely because Mounjaro joined China's national reimbursement list, where the government sets terms.

The launch data make the same point from another direction. More than 20,000 people started Foundayo, Lilly's oral obesity drug, in its first weeks, at over 1,000 a day, and chief executive Dave Ricks said 80% of them had not used a GLP-1 before. Lilly is currently winning new demand, not taking patients from Novo Nordisk. That is good news while the pool of untreated patients is deep, and it means the company's pricing power has not yet been tested against a rival's discount in a market where the easy patients are already treated. An inference, not a reported fact, but the direction is clear.

Regulatory advantage: approval rights with a dated expiry — Moderate

No one sells an incretin without a large outcome-trial program and FDA review, and the agency keeps widening what Lilly's labels can claim. The third-quarter 2026 release lists approvals of Mounjaro to reduce cardiovascular risk in adults with type 2 diabetes, Onswik as a once-weekly basal insulin, Inluriyo with Verzenio in a breast cancer subtype, and an expanded Jaypirca indication. The regulator also closed the compounding route that had let pharmacies copy the drugs during the shortage.

The limit is structural. Regulatory barriers do not erode gradually; they end on a date, and the same rules that protect Lilly protect Novo Nordisk and any future entrant with a differentiated molecule. Exclusivity buys years of protected pricing, and it does nothing to settle which of the two leaders wins the next decade.

Durability: the substitute is the same treatment, cheaper

The threat that matters is not a different kind of therapy. It is an equivalent one at a lower price, or in an easier format. Three versions exist.

A rival's molecule is the first, and Novo Nordisk already supplies it at scale. Compounded or imported copies are the second; they reappear whenever supply tightens or cash-paying patients balk at list price. Orals are the third and the most interesting. A pill skips sterile injectable capacity entirely, which erodes the very asset that supports the supply-side advantage. Lilly hedged by launching its own, and Ricks's comment that most Foundayo starters were new to the drug class suggests the format is bringing in patients rather than cannibalizing pens. If a competitor's oral eventually matches injectable efficacy, the pen franchise loses part of its scarcity value, and Lilly's manufacturing lead in that format matters less.

Cross-price sensitivity is already high in the cash-pay segment, and government purchasers in China and Europe set terms Lilly can accept or refuse. The evidence so far shows volume growth outpacing price declines by enough to raise revenue guidance. It does not yet establish how the balance holds when new-patient growth slows. Two things would settle it: a third supplier winning meaningful formulary access, or a quarter in which volume growth no longer covers the price decline. Neither has happened. Lilly's brand name and cash pile are not the moat; the capacity and the chronic-therapy franchise are, and the second of those is the softer one.

Generated by DeepVal AI. Data and models may contain errors or be outdated. For research only; not personalized investment advice.

Continue the comparison

Continue reading the full report

  1. Comparison and summaryHow Eli Lilly and Company compares with its closest rivals, and our moat rating

Free to sign up · 20 research points · unlocking this report uses 10

20 points cover 2 full reports. No card needed.

Research reflects its generation date. Preview the first two modules.

More on Eli Lilly and Company